Likewise, the AKT inhibitor capivasertib was approved in combination with fulvestrant for patients with advanced breast cancer whose tumors have one or more PIK3CA/AKT1/ PTEN alterations (Nierengarten, 2024), and the mTOR inhibitor everolimus is approved for patients with conditions associated tuberous sclerosis complex with TSC1 or TSC2 mutations that lead to mTOR activation (Previtali et al., 2023). Here, TSC2 is linked to breast cancer.